Bilosomes: A specialized bile salt based nanocarrier drug delivery system in cancer therapy
Abstract
Over the past several years, advances in nanotechnology have given rise to diverse nanocarrier systems tailored for site specific drug delivery. Among these, bilosomes a bile salt stabilized vesicles have emerged as a superior alternative to conventional liposomes and niosomes. This review explores the structural advantages of bilosomes, specifically their enhanced stability within the harsh gastrointestinal (GI) milieu, resistance to enzymatic degradation, and superior mucosal permeability, which collectively enhance the bioavailability of lipophilic and poorly permeable drug therapeutics. A comparative analysis of bilosomal structure relative to liposomal and niosomal frameworks is provided, highlighting the role of various bile salts in modulating vesicle elasticity and drug absorption. The discussion further extends to the preparation methods employed in bilosome formulation and their applications in targeted oncology, evaluating their efficacy in treating breast, skin, lung and liver cancers. Through a synthesis of contemporary case studies, this review examines the mechanistic pathways underlying bilosomes mediated anticancer therapy, while critically assessing their advantages, inherent limitations, and regulatory considerations. Graphical representations are included to illustrate current concepts in bilosomal delivery, offering a comprehensive roadmap for future research in targeted nanomedicine
Keywords: Bilosomes, Nanocarrier, drug delivery system, cancer.
Keywords:
Bilosomes, Nano carriers, Drug delivery systems, CancerDOI
https://doi.org/10.22270/jddt.v16i9.7955References
1. Jiang H, Li AM, Ye J. The magic bullet: Niclosamide. Frontiers in oncology. 2022 Nov 21;12:1004978. https://doi.org/10.3389/fonc.2022.1004978 PMid:36479072 PMCid:PMC9720275
2. Thorburn AL. Paul Ehrlich: pioneer of chemotherapy and cure by arsenic (1854-1915). The British journal of venereal diseases. 1983 Dec;59(6):404-5. https://doi.org/10.1136/sti.59.6.404 PMid:6196079 PMCid:PMC1046247
3. Torchilin VP. Drug targeting. European journal of pharmaceutical sciences. 2000 Oct 1;11:S81-91. https://doi.org/10.1016/S0928-0987(00)00166-4 PMid:11033430
4. Kleinstreuer C, Feng Y, Childress E. Drug-targeting methodologies with applications: A review. World Journal of Clinical Cases: WJCC. 2014 Dec 16;2(12):742. https://doi.org/10.12998/wjcc.v2.i12.742 PMid:25516850 PMCid:PMC4266823
5. Adarsha Ganguly*, Bipasha Pal, Priya Ray, A Thorough Analysis of Targeted Drug Delivery Methods, Int. J. of Pharm. Sci., 2024, 2 (11), 872-877.
6. Ciftci F, Özarslan AC, Kantarci IC, Yelkenci A, Tavukcuoglu O, Ghorbanpour M. Advances in drug targeting, drug delivery, and nanotechnology applications: therapeutic significance in cancer treatment. Pharmaceutics. 2025 Jan 16;17(1):121. https://doi.org/10.3390/pharmaceutics17010121 PMid:39861768 PMCid:PMC11769154
7. Zhuo Y, Zhao YG, Zhang Y. Enhancing drug solubility, bioavailability, and targeted therapeutic applications through magnetic nanoparticles. Molecules. 2024 Oct 13;29(20):4854. https://doi.org/10.3390/molecules29204854 PMid:39459222 PMCid:PMC11510236
8. Md Ikbal Husain, Susmita Sarkar, Nilimanka Das. Bilosomes as Novel Nanocarrier: A Review. Sch Acad J Pharm,2026 Feb 15(2): 32-41. https://doi.org/10.36347/sajp.2026.v15i02.001
9. Kaurav, H.; Tripathi, M.;Kaur, S.D.,et al. Emerging Trends in Bilosomes as Therapeutic DrugDelivery Systems. Pharmaceutics 2024,16, 697. https://doi.org/10.3390/pharmaceutics16060697 PMid:38931820 PMCid:PMC11206586
10. Mitrovi’c, D. etal..A,The Pharmaceutical and Pharmacological Potential Applications of Bilosomes as Nanocarriers for Drug Delivery. Molecules 2025, 30, 1181. https://doi.org/10.3390/molecules30051181 PMid:40076403 PMCid:PMC11901966
11. Pradnya Palekar-Shanbhag, Supriya Lande, et al. Source: Current Drug Therapy, Volume 15, Issue 4, Aug 2020, p. 312-320 https://doi.org/10.2174/1574885514666190917145510
12. Sguizzato, M., Ferrara, F., et al . Bilosomes and Biloparticles for the Delivery of Lipophilic Drugs: A Preliminary Study. Antioxidants, 2023 12(12), https://doi.org/10.3390/antiox12122025 PMid:38136145
13. Ferlay J, Ervik M, Lam F, et al. Global cancer observatory: cancer today. Lyon: International agency for research on cancer. 2020 Nov 25; 20182020:557-67.
14. Source: Institute for Health Metrics and Evaluation https://share.google/xSgrdCxjxDqtuKvL3.
15. Debabrata Dastidar, Dipanjan Ghosh, Amlan Das,Recent developments in nanocarriers for cancer chemotherapy,OpenNano,Volume 8,2022,100080,ISSN 2352-9520, https://doi.org/10.1016/j.onano.2022.100080
16. Gavas, S., Quazi, S., & Karpiński, T. M. Nanoparticles for Cancer Therapy: Current Progress and Challenges. Nanoscale research letters, 2021 16(1), 173. https://doi.org/10.1186/s11671-021-03628-6 PMid:34866166 PMCid:PMC8645667
17. Saiqa Imtiaz, Umme Tamanna Ferdous, et al. ,Mechanistic study of cancer drug delivery: Current techniques,limitations, and future prospects,European Journal of Medicinal Chemistry, ,2025,117535,ISSN 0223-5234, https://doi.org/10.1016/j.ejmech.2025.117535 PMid:40132495
18. Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. International journal of molecular sciences. 2020 May 2;21(9):3233. https://doi.org/10.3390/ijms21093233 PMid:32370233 PMCid:PMC7247559
19. Garg P, Malhotra J, Kulkarni P, Horne D, Salgia R, Singhal SS. Emerging therapeutic strategies to overcome drug resistance in cancer cells. Cancers. 2024 Jul 7;16(13):2478. https://doi.org/10.3390/cancers16132478 PMid:39001539 PMCid:PMC11240358
20. Hu T, Gong H, Xu J, Huang Y, Wu F, He Z. Nanomedicines for overcoming cancer drug resistance. Pharmaceutics. 2022 Aug 1;14(8):1606. https://doi.org/10.3390/pharmaceutics14081606 PMid:36015232 PMCid:PMC9412887
21. Kharouba M, El-Kamel A, Mehanna R, Thabet E, Heikal L. Pitavastatin-loaded bilosomes for oral treatment of hepatocellular carcinoma: a repurposing approach. Drug delivery. 2022 Dec 31;29(1):2925-44. https://doi.org/10.1080/10717544.2022.2120925 PMid:36081339 PMCid:PMC9467608
22. Abd-Elfadel AA, Ewees MG, Aboud HM, El Rouby WM, et al. Evaluating the efficacy of bilosomes as a promising nanovector for methotrexate against breast cancer. Journal of Drug Delivery Science and Technology. 2025 Aug 11:107395. https://doi.org/10.1016/j.jddst.2025.107395
23. Zarenezhad E, Marzi M, Abdulabbas HT, Jasim SA, Kouhpayeh SA, et al. Bilosomes as nanocarriers for the drug and vaccine delivery against gastrointestinal infections: opportunities and challenges. Journal of functional biomaterials. 2023 Sep 1;14(9):453. https://doi.org/10.3390/jfb14090453 PMid:37754867 PMCid:PMC10531812
24. Fu J, Yu M, Xu W, Yu S. Research progress of bile acids in cancer. Frontiers in oncology. 2022 Jan 20;11:778258. https://doi.org/10.3389/fonc.2021.778258 PMid:35127481 PMCid:PMC8810494
25. Krishnamurthy K, Wang G, Rokhfeld D, Bieberich E. Deoxycholate promotes survival of breast cancer cells by reducing the level of pro-apoptotic ceramide. Breast Cancer Research. 2008 Dec 16;10(6):R106. https://doi.org/10.1186/bcr2211 PMid:19087284 PMCid:PMC2656903
26. Tafazzoli Mehrjardi S, Tafaghodi M, Malek S, Yari D, Mohammadpour AH, Kamali H, Nokhodchi A. Intranasal delivery of cetrorelix via lipid liquid crystal nanoparticles: characterization and pharmacokinetic studies in rats. AAPS PharmSciTech. 2025 Jul 1;26(6):176. https://doi.org/10.1208/s12249-025-03169-6 PMid:40593190
27. Hofmann AF, Mysels KJ. Bile salts as biological surfactants. Colloids and Surfaces. 1987 Jan 1;30(1):145-73. https://doi.org/10.1016/0166-6622(87)80207-X
28. Nguyen TT, Ung TT, Kim NH, Do Jung Y. Role of bile acids in colon carcinogenesis. World journal of clinical cases. 2018 Nov 6;6(13):577. https://doi.org/10.12998/wjcc.v6.i13.577 PMid:30430113 PMCid:PMC6232560
29. Smith DL, Keshavan P, Avissar U, Ahmed K, Zucker SD. Sodium taurocholate inhibits intestinal adenoma formation in APC Min/+ mice, potentially through activation of the farnesoid X receptor. Carcinogenesis. 2010 Jun 1;31(6):1100-9. https://doi.org/10.1093/carcin/bgq050 PMid:20194350 PMCid:PMC2878362
30. Rainey JB. Bile acids in experimental colorectal cancer. Annals of the Royal College of Surgeons of England. 1986 May;68(3):130.
31. Gándola YB, Fontana C, Bojorge MA, Luschnat TT, Moretton MA, Chiapetta DA, Verstraeten SV, González L. Concentration-dependent effects of sodium cholate and deoxycholate bile salts on breast cancer cells proliferation and survival. Molecular biology reports. 2020 May;47(5):3521-39. https://doi.org/10.1007/s11033-020-05442-2 PMid:32297292
32. Trah J, Arand J, Oh J, Pagerols-Raluy L, Trochimiuk M, Appl B, Heidelbach H, Vincent D, Saleem MA, Reinshagen K, Mühlig AK. Lithocholic bile acid induces apoptosis in human nephroblastoma cells: A non-selective treatment option. Scientific Reports. 2020 Nov 23;10(1):20349. https://doi.org/10.1038/s41598-020-77436-w PMid:33230229 PMCid:PMC7683553
33. Zhang D, Zhu Y, Su Y, Yu M, Xu X, Wang C, Zhang S, Xia L. Taurochenodeoxycholic acid inhibits the proliferation and invasion of gastric cancer and induces its apoptosis. Journal of food biochemistry. 2022 Mar;46(3):e13866. https://doi.org/10.1111/jfbc.13866
34. Youness RA, Al-Mahallawi AM, Mahmoud FH, Atta H, Braoudaki M, Fahmy SA. Oral delivery of psoralidin by mucoadhesive surface-modified bilosomes showed boosted apoptotic and necrotic effects against breast and lung cancer cells. Polymers. 2023 Mar 15;15(6):1464. https://doi.org/10.3390/polym15061464 PMid:36987244 PMCid:PMC10052996
35. Mohsen AM, Wagdi MA, Salama A. Rutin loaded bilosomes for enhancing the oral activity and nephroprotective effects of rutin in potassium dichromate induced acute nephrotoxicity in rats. Scientific Reports. 2024 Oct 11;14(1):23799. https://doi.org/10.1038/s41598-024-73567-6 PMid:39394242 PMCid:PMC11479598
36. Alruwaili NK, Zafar A, Alsaidan OA, Yasir M, Mostafa EM, Alnomasy SF, Rawaf A, Alquraini A, Alomar FA. Development of surface modified bilosomes for the oral delivery of quercetin: Optimization, characterization in-vitro antioxidant, antimicrobial, and cytotoxicity study. Drug Delivery. 2022 Dec 31;29(1):3035-50. https://doi.org/10.1080/10717544.2022.2122634 PMid:36120935 PMCid:PMC9848422
37. Gad S, Awd H, Abdelwahab N, Nasr A, Ghorab M. Bilosomes as a versatile drug delivery system: preparation techniques and biomedical application. Records of Pharmaceutical and Biomedical Sciences. 2024 May 1;8(3):67-86. https://doi.org/10.21608/rpbs.2024.285225.1294
38. Guan P, Lu Y, Qi J, Wu W. Readily restoring freeze-dried probilosomes as potential nanocarriers for enhancing oral delivery of cyclosporine A. Colloids and Surfaces B: Biointerfaces. 2016 Aug 1;144:143-51. https://doi.org/10.1016/j.colsurfb.2016.04.006 PMid:27085046
39. Castelli G, Pelosi E, Testa U. Liver cancer: molecular characterization, clonal evolution and cancer stem cells. Cancers. 2017 Sep 20;9(9):127. https://doi.org/10.3390/cancers9090127 PMid:28930164 PMCid:PMC5615342
40. Tran TH, Tran PT, Truong DH. Lactoferrin and nanotechnology: The potential for cancer treatment. Pharmaceutics. 2023 Apr 28;15(5):1362. https://doi.org/10.3390/pharmaceutics15051362 PMid:37242604 PMCid:PMC10224286
41. Kamel R, Darwish AB, Youness RA, Basha M. Vesicular Nanosystem as a Promising Platform for the Management of Cancer. InCancer Immunotherapy and Nanobiotechnology: An Interdisciplinary Approach 2024 Aug 21 (pp. 759-795). Cham: Springer Nature Switzerland. https://doi.org/10.1007/16833_2024_329
42. Huang Q, Li F, Liu X, Li W, Shi W, Liu FF, O’sullivan B, He Z, Peng Y, Tan AC, Zhou L. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nature medicine. 2011 Jul;17(7):860-6. https://doi.org/10.1038/nm.2385 PMid:21725296 PMCid:PMC3132290
43. Parashar P, Rana P, Dwivedi M, Saraf SA. Dextrose modified bilosomes for peroral delivery: improved therapeutic potential and stability of silymarin in diethylnitrosamine-induced hepatic carcinoma in rats. Journal of liposome research. 2019 Jul 3;29(3):251-63. https://doi.org/10.1080/08982104.2018.1551408 PMid:30501440
44. Sembiring YE, Effendi WI, Dillon JJ, Soebroto H, Winarno DJ, Puruhito P, Putra IG, Sebayang AN, Negoro SP. Lung cancer: a literature review. Jurnal Respirasi. 2023 Sep 30;9(3):246-51. https://doi.org/10.20473/jr.v9-I.3.2023.246-251
45. Zarenezhad E, Marzi M, Abdulabbas HT, Jasim SA, Kouhpayeh SA, Barbaresi S, Ahmadi S, Ghasemian A. Bilosomes as nanocarriers for the drug and vaccine delivery against gastrointestinal infections: opportunities and challenges. Journal of functional biomaterials. 2023 Sep 1;14(9):453. https://doi.org/10.3390/jfb14090453 PMid:37754867 PMCid:PMC10531812
46. Alhakamy NA, Caruso G, Al-Rabia MW,et al. Piceatannol-loaded bilosome-stabilized zein protein exhibits enhanced cytostatic and apoptotic activities in lung cancer cells. Pharmaceutics. 2021 Apr 29;13(5):638. https://doi.org/10.3390/pharmaceutics13050638 PMid:33947103 PMCid:PMC8146359
47. Hsu SL, Yu CT, Yin SC, Tang MJ, Tien AC, Wu YM, Huang CY. Caspase 3, periodically expressed and activated at G2/M transition, is required for nocodazole-induced mitotic checkpoint. Apoptosis. 2006 May;11(5):765-71. https://doi.org/10.1007/s10495-006-5880-x PMid:16532268
48. Artzy-Schnirman A, Raviv SA, Flikshtain OD, Shklover J, Korin N, Gross A, Mizrahi B, Schroeder A, Sznitman J. Advanced human-relevant in vitro pulmonary platforms for respiratory therapeutics. Advanced drug delivery reviews. 2021 Sep 1;176:113901. https://doi.org/10.1016/j.addr.2021.113901 PMid:34331989 PMCid:PMC7611797
49. Beura PP, Mohapatra SD, Dash A, Satpathy R, Raul SK. Advancement in Green nano-formulation for management of Gynaecological disorders: Emerging trends and Therapeutic insights. Journal of Drug Delivery & Therapeutics. 2026 May 1;16(5):208. https://doi.org/10.22270/jddt.v16i5.7738
50. Kimta N, Majdalawieh MA, Majdalawieh AF. The future of breast cancer treatment: from conventional wisdom to nanotechnology-enabled precision. International journal of molecular sciences. 2026 Feb 24;27(5):2109. https://doi.org/10.3390/ijms27052109 PMid:41828336 PMCid:PMC12984651
51. Abou Assi R, Abdulbaqi IM, Tan SM, Wahab HA, Darwis Y, Chan SY. Breaking barriers: bilosomes gel potentials to pave the way for transdermal breast cancer treatment with tamoxifen. Drug Development and Industrial Pharmacy. 2023 Sep 20:1-2. https://doi.org/10.1080/03639045.2023.2256404 PMid:37722711
52. Zaki RM, Aldosari BN, Alkharashi LA, Alsalhi A, Abo El-Ela FI, Alosaimi RM, Alsunbul M, Afzal O, Said M. Fabrication and appraisal of targeted axitinib loaded bilosomes for the enhanced breast and ovarian anticancer activity. Plos one. 2025 Jul 17;20(7):e0325511. https://doi.org/10.1371/journal.pone.0325511 PMid:40674382 PMCid:PMC12270130
53. Feller L, Khammissa RA, Kramer B, Altini M, Lemmer J. Basal cell carcinoma, squamous cell carcinoma and melanoma of the head and face. Head & face medicine. 2016 Feb 5;12(1):11. https://doi.org/10.1186/s13005-016-0106-0 PMid:26850723 PMCid:PMC4744388
54. Waglewska E, Kulbacka J, Bazylinska U. Superior drug delivery performance of multifunctional bilosomes: innovative strategy to kill skin cancer cells for nanomedicine application. International Journal of Nanomedicine. 2024 Dec 31:4701-17. https://doi.org/10.2147/IJN.S450181 PMid:38808148 PMCid:PMC11131132
55. Demartis S, Rassu G, Murgia S, Casula L, Giunchedi P, Gavini E. Improving dermal delivery of rose bengal by deformable lipid nanovesicles for topical treatment of melanoma. Molecular Pharmaceutics. 2021 Sep 23;18(11):4046. https://doi.org/10.1021/acs.molpharmaceut.1c00468 PMid:34554752 PMCid:PMC8564756
56. Papa V, Furci F, Minciullo PL, Casciaro M, Allegra A, Gangemi S. Photodynamic therapy in cancer: Insights into cellular and molecular pathways. Current Issues in Molecular Biology. 2025 Jan 21;47(2):69. https://doi.org/10.3390/cimb47020069 PMid:39996790 PMCid:PMC11854756
57. Din FU, Aman W, Ullah I, Qureshi OS, Mustapha O, Shafique S, Zeb A. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. International journal of nanomedicine. 2017 Oct 5:7291-309. https://doi.org/10.2147/IJN.S146315 PMid:29042776 PMCid:PMC5634382
58. Peddapalli H, Radha GV, Chinnaiyan SK. Formulation optimization and PK/PD evaluation of novel valsartan bilosomes enhancing transdermal drug delivery. Journal of Drug Delivery Science and Technology. 2024 Feb 1;92:105400. https://doi.org/10.1016/j.jddst.2024.105400
59. Abdullah HD, Kamal I, Sabry SA, Abd Elghany M, El hakim Ramadan A. Effective tailoring of cefepime into bilosomes: a promising nanoplatform for enhancing oral absorption, extending half-life, and evaluating biocompatibility, antibacterial, anti-biofilm, anti-breast cancer activity, ex-vivo, and in-vivo studies. International Journal of Pharmaceutics. 2025 Jan 5;668:125001. https://doi.org/10.1016/j.ijpharm.2024.125001 PMid:39586513
60. Rajput T, Chauhan MK. Bilosome: a bile salt based novel carrier system gaining interest in pharmaceutical research. J Drug Deliv Ther. 2017 Sep 13;7(5):4-16. https://doi.org/10.22270/jddt.v7i5.1479
61. Thirumalai A, Harini K, Pallavi P, Gowtham P, Girigoswami K, Girigoswami A. Bile salt-mediated surface-engineered bilosome-nanocarriers for delivering therapeutics. Nanomedicine Journal. 2024 Jan 1;11(1):1.
62. Ismail A, Teiama M, Magdy B, Sakran W. Development of a novel bilosomal system for improved oral bioavailability of sertraline hydrochloride: Formulation design, in vitro characterization, and ex vivo and in vivo studies. AAPS pharmscitech. 2022 Jul 8;23(6):188. https://doi.org/10.1208/s12249-022-02339-0 PMid:35799076
63. Foulkes R, Man E, Thind J, Yeung S, Joy A, Hoskins C. The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives. Biomaterials science. 2020 Aug 25;8(17):4653-64. https://doi.org/10.1039/D0BM00558D PMid:32672255
64. Paradise J. Regulating nanomedicine at the food and drug administration. AMA journal of ethics. 2019 Apr 1;21(4):347-55. https://doi.org/10.1001/amajethics.2019.347 PMid:31012422
65. Sarella PN, Mangam VT. Enhancing nutraceutical bioavailability with bilosomes: A comprehensive review. Asian Journal of Pharmacy and Technology. 2024 Sep 19;14(3):271-80. https://doi.org/10.52711/2231-5713.2024.00044
66. Rodriguez F, Caruana P, De la Fuente N, Espanol P, Gamez M, Balart J, Llurba E, Rovira R, Ruiz R, Martin-Lorente C, Corchero JL. Nano-based approved pharmaceuticals for cancer treatment: present and future challenges. Biomolecules. 2022 Jun 4;12(6):784. https://doi.org/10.3390/biom12060784 PMid:35740909 PMCid:PMC9221343
67. Zafar A, Alruwaili NK, Imam SS, Alsaidan OA, Yasir M, Ghoneim MM, Alshehri S, Anwer MK, Almurshedi AS, Alanazi AS. Development and evaluation of luteolin loaded pegylated bilosome: optimization, in vitro characterization, and cytotoxicity study. Drug delivery. 2021 Jan 1;28(1):2562-73. https://doi.org/10.1080/10717544.2021.2008055 PMid:34866534 PMCid:PMC8654410
68. Zaki I, Abou-Elkhair RA, Abu Almaaty AH, A. Abu Ali O, Fayad E, Ahmed Gaafar AG, Zakaria MY. Design and synthesis of newly synthesized acrylamide derivatives as potential chemotherapeutic agents against MCF-7 breast cancer cell line lodged on PEGylated bilosomal nano-vesicles for improving cytotoxic activity. Pharmaceuticals. 2021 Oct 4;14(10):1021. https://doi.org/10.3390/ph14101021 PMid:34681245 PMCid:PMC8540948
69. Chettupalli AK, Chokkarapu S, Singh A, Babu MR, Singh MP, Bukke SP. Development and fabrication of a novel nano-bilosomal system for enhanced oral delivery of Trametinib: apoptotic induction and anticancer efficacy evaluation. Materials technology. 2025 Dec 31;40(1):2495346. https://doi.org/10.1080/10667857.2025.2495346
70. Abbas H, El-Feky YA, Al-Sawahli MM, El-Deeb NM, El-Nassan HB, Zewail M. Development and optimization of curcumin analog nano-bilosomes using 21.31 full factorial design for anti-tumor profiles improvement in human hepatocellular carcinoma: in-vitro evaluation, in-vivo safety assay. Drug delivery. 2022 Dec 31;29(1):714-27. https://doi.org/10.1080/10717544.2022.2044938 PMid:35243951 PMCid:PMC8903797
71. Nayak D, Rathnanand M, Tippavajhala VK. Unlocking the potential of bilosomes and modified bilosomes: A comprehensive journey into advanced drug delivery trends. AAPS PharmSciTech. 2023 Nov 21;24(8):238 https://doi.org/10.1208/s12249-023-02696-4 PMid:37989979
Published
Abstract Display: 0 
PDF Downloads: 0 PDF Downloads: 0 How to Cite
Issue
Section
Copyright (c) 2026 Shagufta Rafik Shikalgar, Natalin Marian Veg, Ashwini Ashok Delekar, Shreya Dilip Sangale , Vikas Basu Pawar , Sunita Sakharam Shinde
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.